Allopurinol lowers risk of macular edema among diabetes patients
USA: A recent study published in Ocular Immunology and Inflammation has shown that allopurinol could reduce the risk of diabetic macular edema (DME). DME is one of the major causes of visual loss among patients with diabetes mellitus.Diabetic eye disease is a leading cause of vision loss in people aged 20 to 74. It can affect central vision and lead to vision decline ranging from vision...
USA: A recent study published in Ocular Immunology and Inflammation has shown that allopurinol could reduce the risk of diabetic macular edema (DME). DME is one of the major causes of visual loss among patients with diabetes mellitus.
Diabetic eye disease is a leading cause of vision loss in people aged 20 to 74. It can affect central vision and lead to vision decline ranging from vision blurring to blindness, which can substantially impact the quality of life and independence. Of the visually disabling conditions in patients with diabetic eye disease, DME left untreated, is a frequent cause of vision loss.
For the treatment of macular edema, focal/grid laser photocoagulation has been the standard of care since the 1980s and until 2010. The treatment increases the possibility of vision gain and reduces the risk of vision loss compared with no treatment. Recent phase II and III trials with aflibercept and ranibizumab and phase II trials with bevacizumab, intravitreal injections of anti-vascular endothelial growth factor agents have been revealed to be superior to focal/grid laser for decreasing the risk of vision loss and increasing the possibility of vision gain.
Allopurinol may limit the inflammation-driving diabetic macular edema by inhibiting xanthine oxidase, a subsequent release of inflammatory cytokine leading to the breakdown of the blood–retina barrier.
Considering the above, S. Scott Sutton from the University of South Carolina in Columbia, South Carolina, USA, and colleagues aimed to examine the relationship between allopurinol and diabetic macular edema among type 2 diabetic United States veterans using a retrospective cohort study. For estimating the risk of diabetic macular edema, propensity score matching and Cox hazard models were used.
Propensity score-matched Cox models showed that allopurinol was associated with a 24.6% reduction in the risk of DME (HR = 0.754).
The researchers wrote, "among patients with diabetes mellitus, allopurinol could reduce the risk of diabetic macular edema."
"Further research is warranted into the effects of allopurinol on DME," they concluded.
Reference:
The study, "Allopurinol and the Risk of Diabetic Macular Edema among US Veterans with Type 2 Diabetes," was published in the journal Ocular Immunology and Inflammation. DOI: https://doi.org/10.1080/09273948.2023.2170886
